Podcast appearances and mentions of Benjamin M Greenberg

In this episode of the SRNA "Ask the Expert" podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from "transverse myelitis" to "myelitis" will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis. Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children's Medical Center.Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients. 00:00 Introduction00:58 Overview of Myelitis and Diagnostic Criteria02:57 Historical Context and Importance of Updated Criteria05:10 Challenges with Current Terminology11:10 Changes in Understanding and Diagnostic Approaches17:27 Implications for Patients and Clinical Practice23:40 Impact on Research and Future Directions28:58 Patient Advocacy31:17 Conclusion

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able to: Explain the pathophysiologic rationale for Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) management; Assess emerging evidence on the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able to: Explain the pathophysiologic rationale for Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) management; Assess emerging evidence on the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able to: Explain the pathophysiologic rationale for Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) management; Assess emerging evidence on the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able to: Explain the pathophysiologic rationale for Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) management; Assess emerging evidence on the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities

In Part 7 of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.

Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.

Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.

Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.

In this Part VI of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

In this Part V of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

In this Part IV of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

In this Part III of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

In this Part II of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

In this first part of our Q&A series, Dr. Benjamin M. Greenberg, member of SRNA's Board of Directors and SRNA's Medical and Scientific Council, discussed COVID-19 vaccinations and the implications for those with rare neuroimmune disorders.

Benjamin M. Greenberg, MD, MHS covers the important topic of Incorporating MRI Results in Treatment Decision Making in the format of case-study scenarios for the clinical practice.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Interview with Benjamin M. Greenberg, MD, MHS, author of Herpes Simplex Encephalitis as a Potential Cause of Anti–N-Methyl-D-Aspartate Receptor Antibody Encephalitis: Report of 2 Cases

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.